Formerly the Director of Corporate and Foundation Relations for the Colleges of Science and Engineering at Northeastern University, Catherine brings more than 15 years of fundraising experience to this position. Catherine has previously held progressive institutional fundraising leadership roles at Boston Children’s Hospital, Cambridge College, and Boston University. Catherine received her M.A. with Honors from The Sorbonne University in Paris, France and her B.A. in History from Lyon II University in Lyon, France.
In her new role as Director of Development, Catherine will report to the President & CEO, Isabelle Lousada, and will build on ARC’s established strategic planning process. Catherine will focus on growing the company’s partnerships with patients, researchers, pharmaceutical and biotechnology companies, and establish strategic alliances with other influential stakeholders in the disease community, broaden ARC’s role as a key thought leader in accelerating patient focused drug development in rare diseases and raise ARC’s international profile.
The Amyloidosis Research Consortium (ARC) was founded in 2015 by Isabelle Lousada, an amyloidosis patient. The ARC addresses critical needs in clinical trials and related research to accelerate drug development for the underserved group of rare systemic amyloid diseases and deliver outcomes for patients within an acceptable timeframe. These diseases occur when an abnormal protein called amyloid builds up in the tissues and organs causing damage, organ failure and ultimately death. As a diagnosis of amyloidosis is devastating, the ARC provides resources to help patients navigate the diagnosis, treatment and participation in research.